Etanercept was effective and safe for ankylosing spondylitis.

M a i n o u t c o m e m e a s u r e s The main outcome was treatment response, as measured by the composite end point of ≥ 20% improvement in ≥ 3 of 5 measures of disease activity (morning stiffness, nocturnal spinal pain [100 mm visual analogue scale, 0 = no pain and 100 = most severe pain], functional limitation [10-point scale, 0 = none and 10 = severe limitations], patient global assessment of disease activity [5-point scale, 0 = none and 5 = very severe], and joint swelling).